In financial accounting, a balance sheet is a summary of the financial balances of an individual or organization, whether it be a sole proprietorship, a business partnership, a corporation, private limited company or other organization such as government or not-for-profit entity.

Bio-Gene Technology Limited Balance Sheet Statement - Assets

As of 30 Jun 2025, The total current assets of Bio-Gene Technology Limited (ASX:BGT) was around $1,970,406 which consisted of $1,138,338 of Cash, no Inventory and $472,424 of Net receivables. Current assets represent all the assets of a company that are expected to be conveniently sold, consumed, used, or exhausted through standard business operations within one year.

All amounts in AUD

Cash
$1,138,338
Current assets
$1,970,406
Total assets
$2,149,999

The latest balance sheet of Bio-Gene Technology Limited also showed $13,351 of Property Plant Equipment and no Good will. Also there were $166,242 of Intangible assets and no Other assets. The total assets including current and Intangibles/Deferred Long Term Asset Charges were $2,149,999.

Bio-Gene Technology Limited Balance Sheet Statement - Liabilities

BGT's latest annual results shows the balance sheet has $83,001 of Accounts Payable. Also there were no Short/Long term debt, no Long term debt, $51,209 of Other Current liabilities and $510,131 of Total Current Liabilities. Current liabilities are a company's short-term financial obligations that are due within one year or within a normal operating cycle.

Account payable
$83,001
Current liabilities
$510,131
Total liabilities
$522,983

As per the 30 Jun 2025's annual report of Bio-Gene Technology Limited, the total liabilities were $522,983.

BGT Balance Sheet Statement - Stock Holder Equity

Stockholders' equity, also referred to as shareholders' equity, is the remaining amount of assets available to shareholders after all liabilities have been paid. It is calculated either as a firm's total assets less its total liabilities or alternatively as the sum of share capital and retained earnings less treasury shares. Stockholders' equity might include common stock, paid-in capital, retained earnings and treasury stock.

The latest Balance sheet of Bio-Gene Technology Limited showed the total stock holder equity was $1,627,016 which consisted of $22,944,866 of Common stocks, $-22,029,940 of Retained earnings and no Other stock holder equity.

BGT Balance Sheet Statement History

Following table shows the history of balance sheet for Bio-Gene Technology Limited (BGT).

30 Jun 2025 30 Jun 2024 30 Jun 2023 30 Jun 2022 30 Jun 2021
Cash 1,138,338 2,209,558 2,990,527 6,341,881 -
Net Receivables 472,424 523,958 445,550 438,167 22,000
Inventory - - - - -
Total Current Assets 1,970,406 2,937,395 3,580,466 7,003,092 -
Property Plant Equipment 13,351 19,010 14,639 22,993 -
Good Will - - - - -
Intangible Assets 166,242 203,185 240,128 277,070 -
Other Assets - - - - -
Deferred Long Term Asset Charges - - - - -
Total Assets 2,149,999 3,159,590 3,835,233 7,303,155 -
Accounts Payable 83,001 47,238 118,708 219,006 -
Short/Long Term Debt - - - - -
Other Current Liabilities 51,209 - - 75,000 -
Long Term Debt - - - - -
Other Liabilities - - - - -
Total Current Liabilities 510,131 345,925 573,873 1,009,227 -
Total Liabilities 522,983 368,446 613,884 1,034,682 -
Common Stock 22,944,866 21,524,527 19,545,553 19,545,553 -
Retained Earnings -22,029,940 -19,640,419 -17,432,318 -14,498,875 -
Treasury Stock - - - - -
Other Stockholder Equity - - - - -
Total Stockholder Equity 1,627,016 2,791,144 3,221,349 6,268,473 -
Net Tangible Assets 1,460,774 2,587,959 2,981,221 5,991,403 -

Bio-Gene Technology Limited (ASX:BGT) Balance Sheet Statement FAQ

1. How much Cash Bio-Gene Technology Limited has on their balance sheet?

As of 30 Jun 2025, Bio-Gene Technology Limited (ASX:BGT) has $1,138,338 of Cash.

2. What's the long term debt of Bio-Gene Technology Limited?

As per the latest Balance sheet of Bio-Gene Technology Limited (ASX:BGT), it has no Long term debt.

3. How much share holder equity does Bio-Gene Technology Limited has?

The Bio-Gene Technology Limited (ASX:BGT)'s balance sheet shows that it has $1,627,016 of Total stock holder equity.